Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 4;5(5):1096-1099.
doi: 10.1002/jha2.1027. eCollection 2024 Oct.

Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives

Bert Heyrman  1 , Stef Meers  2 , Sélim Sid  3 , Natalie Put  4 , Koen Theunissen  5 , Koen Van Eygen  6 , Nathan De Beule  7 , Maxime Clauwaert  8 , Helena Maes  9 , Alexander Salembier  10 , Jan Lemmens  11 , Ann Van De Velde  12 , Dominik Selleslag  13 , Jason Bouziotis  14 , Ann De Becker  7 , Sébastien Anguille  12
Affiliations

Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives

Bert Heyrman et al. EJHaem. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare to have no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
The median [interquartile range {IQR}] duration of treatment in patients who did not respond was 23.9 [18; 48] weeks. In the responding group, the duration of treatment was at least 38 weeks in 75% of patients and the median duration was 83.1 weeks.
See this image and copyright information in PMC

References

    1. Meers S. The myelodysplastic syndromes: the era of understanding. Eur J Haematol. 2015;94(5):379–90. 10.1111/ejh.12443 - DOI - PubMed
    1. Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T)—“2021 update on diagnosis, risk‐stratification, and management”. Am J Hematol. 2021;96(3):379–394. 10.1002/ajh.26090 - DOI - PubMed
    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDeO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. 10.1038/s41375-022-01620-2 - DOI - PMC - PubMed
    1. Park S, Grabar S, Kelaidi C, Beyne‐Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G‐CSF: the GFM experience. Blood. 2008;111(2):574–582. 10.1182/blood-2007-06-096370 - DOI - PubMed
    1. Oliva EN, Platzbecker U, Fenaux P, Garcia‐Manero G, Leblanc TW, Patel BJ, et al. Targeting health‐related quality of life in patients with myelodysplastic syndromes – current knowledge and lessons to be learned. Blood Rev. 2021;50:100851. doi: 10.1016/j.blre.2021.100851 - DOI - PubMed

LinkOut - more resources